

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2024/048782 A1

(43) International Publication Date
07 March 2024 (07.03.2024)

(51) International Patent Classification:

A61K 9/16 (2006.01) *A61P 25/24* (2006.01)
A61K 9/50 (2006.01) *A61K 31/403* (2006.01)
A61K 45/06 (2006.01) *A61K 31/343* (2006.01)

(21) International Application Number:

PCT/JP2023/032094

(22) International Filing Date:

01 September 2023 (01.09.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/403,624 02 September 2022 (02.09.2022) US

(71) Applicant: OTSUKA PHARMACEUTICAL CO., LTD.

[JP/JP]; 2-9, Kanda Tsukasa-machi, Chiyoda-ku, Tokyo,
1018535 (JP).

(72) Inventors: KOHEGYI, Eva; 534 Old Mill Dr., Langhorne,

Pennsylvania, 19047 (US). ROTHMAN, Brian; 1046 W
Edgeware Road, Los Angeles, California, 90026 (US).

(74) Agent: YAMAO, Norihito et al.; AOYAMA & PART-

NERS, Osaka Umeda Twin Towers North, 8-1, Kaku-
da-cho, Kita-ku, Osaka-shi, Osaka, 5300017 (JP).

(81) Designated States (*unless otherwise indicated, for every*

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every*

kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: 1-(NAPHTHALEN-2-YL)-3-AZABICYCLO[3.1.0]HEXANE FOR TREATING MAJOR DEPRESSIVE DISORDER

(57) Abstract: The disclosure relates generally to methods of treating central nervous system disorders using (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane (i.e. centanafadine) or a pharmaceutically acceptable salt thereof. More particularly, the disclosure relates to treating conditions affected by monoamine neurotransmitters.

WO 2024/048782 A1